tradit
vaccin
develop
platform
liveattenu
viru
kill
viru
recombin
subunitbas
vaccin
often
effect
elicit
longterm
immun
number
infecti
human
pathogen
howev
mani
human
pathogen
vaccin
platform
unsuit
human
use
due
safeti
concern
poor
efficaci
simpl
impract
result
much
work
focus
use
recombin
viru
vector
mean
vaccin
human
pathogen
viral
vector
express
foreign
protein
high
level
host
cell
result
strong
longlast
immun
respons
target
protein
chapter
describ
use
viru
vector
context
vaccin
human
pathogen
variou
vector
platform
discuss
compar
contrast
tradit
vaccin
platform
liveattenu
kill
viru
vaccin
use
success
decad
approach
appli
mani
differ
human
diseas
includ
smallpox
polio
measl
mump
yellow
fever
rubella
influenza
varicella
hepat
form
vaccin
develop
effect
particular
support
demonstr
erad
smallpox
near
erad
polio
global
vaccin
effort
compar
inactivatedkil
viru
vaccin
liveattenu
vaccin
gener
thought
provid
longerlast
immun
without
need
repeat
booster
immun
econom
simpl
mean
high
efficaci
vaccin
product
howev
develop
liveattenu
viru
vaccin
human
pathogen
encount
safeti
concern
due
underattenu
viru
even
revers
pathogen
state
exampl
effort
develop
hiv
vaccin
research
investig
liveattenu
simian
immunodefici
viru
siv
vaccin
proof
principl
found
strong
level
protect
nonhuman
primat
johnson
desrosi
unfortun
liveattenu
siv
vaccin
also
caus
aid
vaccin
monkey
due
revers
pathogen
form
baba
et
al
berkhout
et
al
frequent
sourc
controversi
field
murpheycorb
similar
find
note
experiment
liveattenu
vaccin
exampl
liveattenu
dengu
viru
vaccin
also
show
protect
immun
anim
model
blaney
et
al
howev
phase
clinic
trial
involv
liveattenu
dengu
viru
vaccin
formul
halt
due
side
effect
caus
underattenu
vaccin
viru
strain
kitchen
et
al
obvious
fine
balanc
develop
safe
attenu
viru
strain
develop
one
maintain
high
level
immunogen
unfortun
immunogen
liveattenu
vaccin
often
gain
cost
clinic
safeti
vice
versa
even
licens
liveattenu
vaccin
approv
use
decad
without
risk
vaccinemedi
diseas
classic
exampl
smallpox
vaccin
centuri
variola
vaccin
tradit
perform
use
relat
less
pathogen
poxviru
vaccinia
viru
howev
earli
vaccin
strain
vaccinia
well
known
induc
signific
side
effect
vaccin
recipi
even
lifethreaten
parrino
graham
upon
vaccin
plasmid
dna
taken
local
cell
inject
site
gene
express
produc
pathogen
protein
form
de
novo
protein
express
elimin
need
purif
larg
amount
protein
sinc
actual
protein
express
cell
vivo
potenti
efficaci
vaccin
platform
success
demonstr
numer
pathogen
includ
ebola
viru
vanderzanden
et
al
xu
et
al
avian
influenza
kodih
et
al
tompkin
et
al
dengu
viru
apt
et
al
west
nile
viru
bun
et
al
hiv
cherp
et
al
major
limit
dna
vaccin
level
express
gene
interest
compar
mean
gene
express
viral
vector
express
dna
vaccin
notori
weak
vivo
result
lower
immunogen
vaccin
thu
mani
dna
vaccin
studi
anim
model
employ
system
dna
vaccin
prime
follow
viral
vector
protein
subunit
booster
immun
shu
et
al
sullivan
et
al
wu
et
al
zanin
et
al
one
promis
recombin
vaccin
technolog
platform
viral
vector
premis
behind
use
viral
vector
mean
vaccin
present
natur
occur
form
target
pathogen
antigen
immun
system
absenc
infecti
pathogen
process
induc
immun
respons
target
pathogen
antigen
similar
natur
infect
howev
absenc
diseas
one
earliest
demonstr
scientist
wistar
institut
engin
vaccinia
viru
vector
express
rabi
viru
glycoprotein
success
protect
mice
rabbit
lethal
rabi
viru
challeng
wiktor
et
al
vaccin
sinc
licens
market
veterinari
vaccin
merial
rabor
vrg
commonli
use
mass
vaccin
certain
speci
wildlif
order
curtail
spread
rabi
wild
mackowiak
et
al
see
chapter
technolog
advanc
list
viral
vector
use
experiment
vaccin
vector
base
adenoviru
adenoassoci
viru
aav
vesicular
stomat
viru
vsv
alphaviru
studi
numer
front
vaccin
tool
brave
et
al
other
discuss
chapter
perhap
wide
studi
viral
vector
vaccin
gene
therapi
applic
adenoviru
goncalv
de
vri
adenovirus
ad
belong
famili
adenovirida
doublestrand
dna
virus
genom
size
approxim
kbp
ad
infect
wide
rang
speci
maintain
high
level
speci
specif
human
ad
least
differ
serotyp
identifi
shenk
studi
term
viral
vector
serotyp
respect
ad
common
wellcharacter
genom
easi
manipul
grown
purifi
high
titer
cell
cultur
abl
infect
wide
varieti
divid
nondivid
cell
type
express
high
level
recombin
transgen
infect
cell
favor
safeti
profil
properti
culmin
use
ad
vector
hundr
human
clinic
trial
around
world
varieti
medic
applic
includ
cancer
gene
therapi
vaccin
vector
earli
work
ad
molecular
biolog
found
virus
abl
packag
genom
size
wildtyp
genom
length
infecti
viral
particl
equat
approxim
kb
exogen
dna
transgen
could
insert
wildtyp
ad
genom
ghoshchoudhuri
et
al
graham
et
al
howev
increas
genom
length
beyond
wildtyp
genom
length
result
genet
instabl
loss
transgen
bett
et
al
research
quickli
discov
genom
space
could
creat
larger
transgen
specif
delet
ad
genom
first
delet
direct
toward
ad
earli
gene
also
creat
replicationincompet
vector
loss
subsequ
inhibit
downstream
transcript
ad
gene
necessari
replic
jone
shenk
replicationincompet
vector
replic
permiss
cell
line
human
embryon
kidney
cell
line
graham
et
al
provid
miss
gene
function
ad
vector
tran
addit
delet
region
ad
genom
ampl
space
exist
insert
foreign
dna
sequenc
delet
ad
vector
refer
firstgener
vector
usual
kb
genom
space
avail
transgen
insert
ghoshchoudhuri
et
al
graham
firstgener
ad
vector
effect
tool
gene
deliveri
durat
transgen
express
fairli
limit
due
host
immun
respons
ad
protein
express
vector
protein
therefor
effort
made
reduc
amount
ad
protein
express
vector
maintain
high
level
transgen
express
achiev
partial
delet
region
hodg
antibodi
particular
common
serotyp
use
experiment
ad
vector
nwanegbo
et
al
thought
circul
adneutr
antibodi
might
limit
adbas
vaccin
vector
efficaci
neutral
vector
prior
effici
transgen
express
experiment
shown
variou
anim
model
immun
studi
establish
anim
inocul
anim
multipl
time
high
dose
wildtyp
unrel
vector
follow
vaccin
experiment
vector
invari
fail
due
preexist
immun
capon
et
al
hashimoto
et
al
kobing
et
al
xiang
et
al
studi
demonstr
feasibl
overcom
preexist
immun
use
ad
vector
base
altern
serotyp
antigen
distinct
thu
neutral
immun
respons
howev
conflict
data
gener
human
clinic
trial
phase
iii
clinic
trial
involv
merck
adbas
hiv
vaccin
found
preexist
immun
limit
vaccin
efficaci
lower
vaccin
dose
limit
could
complet
overcom
increas
dose
vaccin
cohen
support
produc
clinic
trial
studi
adbas
influenza
vaccin
show
correl
level
antibodi
immunogen
vaccin
van
kampen
et
al
final
suggest
vaccin
altern
rout
administr
oral
intranas
rather
inject
overcom
preexist
vector
immun
appaiahgari
et
al
xiang
et
al
support
data
human
clinic
trial
van
kampen
et
al
luski
et
al
moorhead
et
al
region
dedieu
et
al
gao
et
al
ad
genom
reduc
elimin
express
protein
type
ad
vector
refer
secondgener
vector
increas
transgen
insert
capac
approxim
kb
transgen
capac
increas
even
advanc
ad
vector
delet
exclud
open
read
frame
wang
et
al
ad
vector
highest
capac
exogen
dna
call
gutless
vector
consist
sole
exogen
transgen
dna
flank
ad
invert
termin
repeat
itr
sequenc
ad
packag
signal
vector
accommod
kb
foreign
dna
tabl
although
must
propag
use
helper
viru
provid
miss
ad
gene
necessari
replic
packag
cell
line
kochanek
et
al
kumarsingh
chamberlain
park
et
al
ad
vector
studi
numer
front
avian
influenza
ebola
marburg
virus
sullivan
et
al
sullivan
et
al
wang
et
al
wang
et
al
west
nile
viru
scheppberglind
et
al
dengu
viru
jaiswal
et
al
raja
et
al
sarscov
hiv
barouch
nabel
catanzaro
et
al
anthrax
mcconnel
et
al
addit
ad
vector
studi
potenti
gene
therapi
vector
mani
type
cancer
diseas
hundr
human
clinic
trial
wwwclinicaltrialsgov
one
primari
critic
ad
vector
use
human
issu
preexist
immun
ad
infect
quit
common
human
result
popul
neutral
preexist
ad
vector
immun
sourc
frequent
debat
signific
factor
adbas
vaccin
vector
certain
condit
howev
experiment
data
exist
support
side
argument
remain
seen
difficulti
demonstr
preexist
immun
anim
model
translat
actual
scenario
human
vaccin
data
produc
clinic
trial
better
understand
true
signific
preexist
immun
adbas
vaccin
vector
aav
belong
famili
parvovirida
small
singlestrand
dna
virus
genom
size
approxim
kb
eight
known
aav
serotyp
commonli
studi
chiorini
et
al
chiorini
et
al
gao
et
al
muramatsu
et
al
rutledg
et
al
xiao
et
al
aav
quit
uniqu
order
replic
requir
coinfect
helper
viru
ad
atchison
et
al
herp
viru
buller
et
al
absenc
helper
viru
aav
infect
becom
latent
produc
progeni
viru
howev
product
infect
achiev
latent
infect
cell
subsequ
infect
ad
herp
helper
virus
bern
linden
wildtyp
aav
caus
human
diseas
give
excel
safeti
profil
potenti
therapeut
vaccin
vector
aav
broad
host
rang
persist
transgen
express
host
cell
gener
weak
antivector
immun
respons
qualiti
led
intens
studi
aav
tool
human
gene
therapi
recombin
vaccin
vector
recombin
aav
vector
studi
vaccin
vector
herp
simplex
viru
type
man
et
al
human
papilloma
viru
hiv
xin
et
al
cytomegaloviru
gallezhawkin
et
al
studi
found
recombin
aav
raav
platform
effect
mean
induc
potent
immun
respons
target
pathogen
due
small
size
aav
genom
raav
vector
accommod
approxim
kb
exogen
dna
usual
done
remov
viral
gene
termin
repeat
tr
sequenc
replac
desir
transgen
dong
et
al
sinc
viral
dna
sequenc
raav
vector
retain
tr
vector
must
propag
special
packag
cell
line
express
aav
rep
cap
protein
addit
helper
viru
coinfect
vincent
et
al
advantag
disadvantag
advantag
recombin
viral
vector
complet
void
parent
viru
gene
lack
aav
protein
express
upon
transduct
host
cell
result
low
level
antivector
immun
gener
vaccin
howev
disadvantag
small
genom
size
requir
helper
viru
propag
addit
aav
infect
occur
absenc
helper
viru
becom
latent
integr
viral
genom
host
dna
specif
site
human
chromosom
cheung
et
al
samulski
et
al
viru
integr
dna
host
genom
rais
safeti
concern
genet
consequ
integr
integr
viral
dna
benefici
desir
transgen
persist
express
desir
outcom
gene
therapi
studi
howev
may
also
detriment
host
integr
result
mutat
delet
host
dna
mccarti
et
al
similar
ad
vector
potenti
pitfal
raav
vector
issu
preexist
vector
immun
initi
thought
aav
nonpathogen
weakli
immunogen
thu
creat
perfect
gene
transfer
vehicl
immunolog
invis
initi
suggest
spearhead
movement
use
raav
vector
gene
therapi
vaccin
vector
develop
howev
known
human
inde
circul
antibodi
crossreact
aav
seroposit
aav
neutral
antibodi
kotin
furthermor
highest
level
human
aav
antibodi
direct
toward
capsid
protein
serotyp
common
serotyp
use
backbon
vaccin
vector
howev
eight
differ
aav
serotyp
use
altern
serotyp
vector
backbon
may
mean
overcom
preexist
immun
hurdl
davidoff
et
al
human
clinic
trial
data
need
order
better
gaug
signific
preexist
vector
immun
use
raav
vaccin
vector
note
juli
us
food
drug
administr
announc
death
clinic
trial
particip
involv
aavbas
rheumatoid
arthriti
treatment
fda
date
chapter
review
detail
tragedi
yet
releas
fda
clinic
trial
sponsor
alphavirus
belong
famili
togavirida
small
envelop
virus
singlestrand
alphavirus
alphaviru
vaccin
vector
studi
vaccin
avian
influenza
schultzcherri
et
al
ebola
viru
oling
et
al
pushko
et
al
marburg
viru
hevey
et
al
lee
et
al
hiv
meged
et
al
cytomegaloviru
reap
et
al
sarscov
deme
et
al
anthrax
botulinum
toxin
lee
et
al
addit
vee
replicon
contain
hiv
gene
test
phase
clinic
trial
well
toler
vaccin
recipi
although
immunogen
moder
chulay
et
al
phase
studi
alphaviru
replicon
hiv
cytomegaloviru
vaccin
current
recruit
subject
wwwclinicaltrialsgov
alphaviru
vaccin
vector
must
also
face
issu
preexist
immun
although
like
signific
hurdl
vector
adenoviru
describ
larg
alphavirus
zoonot
mosquitoborn
virus
endem
certain
geograph
region
world
furthermor
human
alphaviru
epidem
occur
infrequ
suggest
gener
popul
littl
preexist
vector
immun
alphavirusbas
vaccin
vector
howev
suggest
earli
hors
preexist
antibodi
one
strain
alphaviru
interfer
infect
alphaviru
strain
calish
et
al
could
pose
problem
repeat
vaccin
human
use
alphaviru
replicon
exampl
antivector
immun
gener
vaccin
vee
replicon
could
subsequ
imped
booster
vaccin
even
differ
alphaviru
replicon
inde
evid
human
immun
respons
gener
vaccin
one
alphaviru
interfer
immun
respons
gener
subsequ
vaccin
differ
alphavirus
mcclain
et
al
newcastl
diseas
viru
ndv
belong
famili
paramyxovirida
zoonot
viru
natur
infect
speci
bird
ndv
genom
nonseg
singl
strand
negativesens
rna
approxim
kb
length
ndv
antigen
distinct
human
paramyxovirus
human
parainfluenza
virus
led
interest
use
vaccin
vector
human
ndv
categor
three
group
base
level
pathogen
chicken
avirul
lentogen
strain
moder
pathogen
mesogen
posit
rna
genom
approxim
kb
alphavirus
arthropodborn
virus
arbovirus
group
six
clade
base
antigen
homolog
glycoprotein
barmah
forest
bf
ndumu
ndu
semliki
forest
sf
western
equin
enceph
wee
eastern
equin
enceph
eee
venezuelan
equin
enceph
vee
griffin
three
primari
alphavirus
use
backbon
recombin
vaccin
vector
sf
sindbi
viru
sin
vee
liljestrom
garoff
pushko
et
al
xiong
et
al
alphavirus
known
broad
host
rang
infect
varieti
cell
type
includ
dendrit
cell
major
antigenpres
cell
gardner
et
al
macdonald
johnston
thought
import
advantag
use
alphavirus
vaccin
vector
directli
target
dendrit
cell
vivo
induc
rapid
strong
immun
respons
primari
method
use
alphavirus
vaccin
vector
creat
known
replicon
entail
delet
alphaviru
structur
gene
viru
genom
replac
transgen
interest
recombin
rna
molecul
must
coexpress
packag
cell
line
helper
rna
contain
miss
structur
gene
order
effect
packag
recombin
rna
infecti
viral
particl
bredenbeek
et
al
liljestrom
garoff
thu
replicon
envelop
viral
particl
contain
recombin
genom
transduc
cell
express
transgen
high
level
sinc
recombin
genom
lack
alphaviru
structur
gene
progeni
viru
produc
replicon
transduct
one
pitfal
notic
earli
alphaviru
replicon
develop
recombin
helper
rna
contain
structur
gene
recombin
rna
lack
structur
gene
contain
packag
signal
packag
cell
line
produc
replicationcompet
alphaviru
particl
berglund
et
al
gener
contamin
replicationcompet
viru
seriou
safeti
concern
vaccin
vector
platform
howev
endeavor
made
design
newer
advanc
helper
rna
molecul
packag
cell
line
reduc
possibl
produc
replicationcompet
alphaviru
particl
contamin
polo
et
al
smerdou
liljestrom
addit
shortcom
alphaviru
vaccin
vector
genom
capac
transgen
insert
despit
complet
remov
alphaviru
structur
gene
vector
genom
recombin
replicon
accommod
transgen
insert
approxim
kb
smerdou
liljestrom
strain
highli
pathogen
velogen
strain
lentogen
strain
wide
use
ndv
liveattenu
viru
vaccin
poultri
industri
outbreak
newcastl
diseas
quit
sever
poultri
constant
threat
industri
worldwid
howev
ndv
nonpathogen
primat
bukreyev
et
al
led
studi
vaccin
vector
construct
recombin
ndv
vaccin
vector
gener
entail
first
modifi
packag
cell
cultur
either
stabl
express
techniqu
romeroberdorf
et
al
infect
helper
viru
huang
et
al
nakaya
et
al
express
dnadependentrna
polymeras
cell
transfect
fulllength
ndv
revers
sens
cdna
contain
exogen
transgen
well
sever
dna
support
plasmid
carri
gene
ndv
transcriptas
complex
nucleocapsid
protein
np
phosphoprotein
p
rnadependentrna
polymeras
protein
l
huang
et
al
huang
et
al
nakaya
et
al
incub
produc
recombin
viru
rescu
propag
embryon
chicken
egg
ndv
studi
recombin
vaccin
vector
sarscov
dinapoli
et
al
respiratori
syncyti
viru
martinezsobrido
et
al
siv
nakaya
et
al
influenza
viru
nakaya
et
al
despit
danger
ndv
poultri
virus
favor
safeti
profil
use
human
support
high
level
attenu
seen
nonhuman
primat
anim
model
vaccin
bukreyev
et
al
well
safe
administr
oncolyt
ndv
human
phase
clinic
trial
lorenc
et
al
lorenc
et
al
paramyxovirus
also
studi
experiment
vaccin
vector
sendai
viru
griesenbach
et
al
takimoto
et
al
simian
viru
park
alexandermil
sinc
ndv
avian
paramyxoviru
issu
antivector
preexist
immun
consid
signific
factor
vaccin
platform
major
advantag
addit
sever
ndv
strain
licens
use
veterinari
vaccin
make
well
character
readili
avail
recombin
ndv
vector
propag
high
titer
chicken
egg
even
cell
line
although
inclus
even
small
exogen
transgen
significantli
lower
yield
recombin
viru
krishnamurthi
et
al
also
rule
six
accord
sendai
viru
studi
indic
total
viral
genom
length
transgen
includ
must
divis
six
order
proper
np
function
transcriptas
complex
calain
roux
nakaya
et
al
may
complic
strategi
vaccin
vector
construct
furthermor
ndv
vector
may
somewhat
limit
capac
larg
transgen
insert
earli
studi
sendai
viru
indic
maximum
insert
size
kb
without
signific
genet
instabl
reduct
viral
yield
sakai
et
al
although
recent
sendai
viru
vector
shown
accommod
kb
exogen
dna
poxvirus
larg
doublestrand
dna
virus
famili
poxvirida
compar
virus
mention
chapter
poxvirus
far
largest
viron
size
nm
well
genom
length
reach
kb
type
poxvirus
notori
virul
poxvirus
variola
viru
orthopoxviru
genu
oblig
human
pathogen
caus
smallpox
three
notabl
orthopoxvirus
vaccinia
monkeypox
cowpox
virus
zoonot
virus
caus
less
sever
diseas
human
compar
variola
vaccinia
viru
often
consid
prototyp
poxviru
heavili
investig
number
research
endeavor
thu
well
character
much
vaccinia
fame
stem
use
liveattenu
smallpox
vaccin
global
vaccin
effort
ultim
led
erad
smallpox
poxvirus
genu
avipoxviru
receiv
great
deal
research
attent
potenti
vaccin
vector
virus
zoonot
arbovirus
natur
infect
bird
nonpathogen
human
qualiti
addit
larg
kb
genom
make
avipox
virus
attract
research
tool
exampl
fowlpox
canarypox
virus
test
anim
model
vaccin
vector
rabi
taylor
et
al
taylor
et
al
avian
influenza
steensel
et
al
nipah
viru
weingartl
et
al
hiv
gilbert
et
al
radaelli
et
al
zhang
et
al
safeti
avipox
viru
vector
human
demonstr
clinic
trial
vaccin
vector
hiv
emeri
et
al
russel
et
al
malaria
walther
et
al
well
numer
cancer
gene
therapi
clinic
trial
wwwclinicaltrialsgov
vaccinia
viru
use
decad
smallpox
vaccin
human
earlier
strain
vaccinia
known
signific
side
effect
vaccin
recipi
newer
strain
develop
modifi
previous
exist
vaccin
immun
respons
mice
vaccinia
viru
vector
express
transgen
maeda
et
al
vsv
zoonot
arboviru
belong
famili
rhabdovirida
famili
rabi
virus
vsv
kb
genom
consist
singl
strand
negativesens
rna
vsv
transmiss
anim
occur
insect
bite
caus
sever
diseas
cattl
hors
swine
symptom
similar
foot
mouth
diseas
rodriguez
human
vsv
infect
occur
although
much
less
frequent
anim
much
less
sever
diseas
symptom
usual
mild
flulik
ill
mani
human
infect
even
go
unnot
complet
asymptomat
howev
rare
case
sever
diseas
report
quiroz
et
al
recombin
vsv
accommod
increas
genom
size
approxim
kb
transgen
insert
slight
reduct
infect
titer
haglund
et
al
addit
eas
genom
modif
vsv
vector
ad
advantag
viru
effici
incorpor
express
foreign
transmembran
protein
surfac
recombin
viral
particl
schubert
et
al
coupl
rel
safe
background
rare
seropreval
human
make
vsv
attract
platform
vaccin
vector
develop
concern
vsv
vector
safeti
relat
possibl
sever
human
diseas
quiroz
et
al
well
neurovirul
mortal
rate
experiment
intranas
mous
infect
reiss
et
al
addit
asymptomat
brain
infect
note
cotton
rat
intrans
deliveri
recombin
vsv
vector
schlereth
et
al
howev
recent
studi
shown
intranas
deliveri
vsv
spread
cn
tissu
nonhuman
primat
indic
vector
may
safer
initi
suggest
johnson
et
al
thu
recombin
vsv
vector
studi
vaccin
avian
influenza
viru
schwartz
et
al
ebola
marburg
virus
daddariodicaprio
et
al
feldmann
et
al
jone
et
al
plagu
palin
et
al
hepat
c
viru
ezel
et
al
hiv
haglund
et
al
haglund
et
al
vsv
vaccin
vector
yet
test
human
result
anim
model
vaccin
encourag
preexist
vector
immun
thought
signific
factor
use
vsv
vaccin
vector
strain
favor
safeti
profil
human
use
parrino
graham
see
chapter
improv
safeti
profil
vaccinia
viru
strain
led
studi
use
vaccin
vector
diseas
exampl
replic
defect
vaccinia
strain
modifi
vaccinia
ankara
mva
genet
modifi
express
gene
hiv
herp
simplex
viru
type
meseda
et
al
rabi
viru
weyer
et
al
cytomegaloviru
signific
differ
vaccinia
avipox
virus
possibl
preexist
vector
immun
sinc
avipox
virus
zoonot
natur
infect
bird
gener
popul
littl
preexist
immun
virus
like
avipox
virus
vaccinia
also
consid
zoonot
viru
possibl
distantli
relat
cowpox
buffalopox
virus
exact
origin
unknown
contrast
avipox
virus
howev
much
adult
popul
today
seroposit
vaccinia
due
childhood
smallpox
vaccin
data
suggest
vacciniabas
vaccin
vector
would
ineffect
individu
due
antivector
immun
belyakov
et
al
suggest
vaccin
mucos
rout
administr
may
effect
mean
overcom
vacciniadirect
vector
immun
belyakov
et
al
naito
et
al
larg
genom
size
poxvirus
somewhat
doubleedg
sword
vector
develop
one
hand
ampl
capac
larg
transgen
insert
size
reach
least
kb
recombin
vaccinia
viru
smith
moss
hand
vector
express
hundr
nativ
viru
protein
addit
transgen
interest
induc
strong
immun
respons
vector
protein
subsequ
reduc
capac
strong
immun
respons
transgen
product
due
immun
dilut
effect
could
explan
poor
perform
poxviru
vector
human
clinic
trial
exampl
fowlpox
canarypox
vaccinia
viru
vector
test
human
found
safe
howev
fowlpox
canarypox
vector
contain
hiv
gene
induc
littl
antihiv
cellular
immun
respons
human
emeri
et
al
russel
et
al
similar
result
report
fowlpoxbas
malaria
vaccin
induc
moder
immun
respons
show
extrem
poor
efficaci
walther
et
al
vaccinia
viru
vector
also
document
induc
weak
cellular
immun
respons
direct
comparison
recombin
ad
vector
express
nucleoprotein
gene
sin
nombr
viru
member
hantaviru
genu
induc
much
stronger
cellular
human
sinc
vsv
zoonot
viru
human
infect
gener
limit
isol
geograph
region
world
individu
close
contact
infect
anim
thu
global
seropreval
vsv
consid
low
howev
anim
model
show
vaccin
recombin
vsv
vector
induc
neutral
antibodi
vsv
envelop
protein
robert
et
al
therefor
likelihood
human
receiv
vsvbase
vaccin
vector
develop
neutral
immun
respons
viral
envelop
protein
would
reduc
efficaci
subsequ
vsvbase
booster
vaccin
similar
ad
aav
vector
strategi
describ
serotyp
rotat
differ
vsv
glycoprotein
report
bypass
level
antivector
immun
induc
primari
vaccin
addit
viral
vector
describ
sever
other
investig
util
gene
therapi
vaccin
applic
herp
simplex
virus
hsv
doublestrand
dna
virus
famili
herpesvirida
hsv
subtyp
well
known
caus
human
herp
infect
also
studi
vaccin
vector
siv
kaur
et
al
hiv
santo
et
al
intracellular
bacteri
pathogen
lauterbach
et
al
measl
viru
mv
paramyxovirida
famili
wellknown
childhood
pathogen
despit
avail
effect
vaccin
still
caus
signific
mortal
children
develop
countri
use
rescu
techniqu
similar
describ
construct
ndv
vector
mv
vector
develop
number
vaccin
candid
advantag
mv
vector
thought
possibl
multival
vaccin
children
mv
vector
express
gene
pathogen
hepat
b
viru
rey
del
vall
et
al
west
nile
viru
despr
et
al
hiv
lorin
et
al
could
serv
bival
vaccin
mv
pathogen
howev
much
like
vaccinia
vector
major
portion
adult
popul
immun
recombin
measl
vector
due
childhood
measl
infect
measl
vaccin
poliovirus
member
picornavirida
famili
famili
contain
foot
mouth
diseas
hepat
virus
polioviru
well
known
caus
paralyt
poliomyel
nearli
erad
due
develop
success
safe
inactiv
liveattenu
polioviru
vaccin
sinc
attenu
viru
strain
safe
use
human
research
studi
possibl
use
polioviru
vector
pathogen
andino
et
al
hepat
b
viru
yim
et
al
siv
tang
et
al
howev
vast
major
world
popul
immun
polioviru
childhood
vaccin
make
poliovirusvector
vaccin
somewhat
impract
adult
conclus
viral
vector
use
present
natur
form
viral
antigen
immun
system
gener
speak
viral
vector
favor
safeti
profil
mani
liveattenu
viru
vaccin
immunogen
inactivatedkil
viru
vaccin
furthermor
viral
vector
vaccin
present
desir
antigen
natur
correct
conform
immun
system
process
poorli
achiev
recombin
protein
subunit
vaccin
final
viral
vector
vaccin
express
higher
level
foreign
gene
vivo
longer
durat
compar
dna
vaccin
three
major
consider
exist
use
viral
vector
vaccin
human
first
safeti
platform
ad
vector
test
extens
human
clinic
trial
mani
year
accept
safe
human
use
platform
vsv
still
infanc
human
safeti
remain
unknown
factor
clinic
trial
take
place
gain
better
understand
vector
perform
human
second
consider
preexist
vector
immun
vari
signific
depend
vector
choic
ad
vaccinia
vector
may
seriou
impact
vaccin
vector
efficaci
human
zoonot
viru
vector
avipox
virus
ndv
preexist
immun
like
play
signific
role
development
clinic
applic
final
third
consider
vaccin
vector
develop
vector
genom
capac
transgen
insert
depend
vector
exogen
dna
sequenc
rang
length
less
kb
kb
howev
increas
transgen
size
often
come
genet
instabl
decreas
viru
yield
product
must
factor
togeth
determin
ideal
viru
vaccin
vector
suitabl
use
human
also
maintain
high
level
efficaci
viral
vector
mention
chapter
repres
portion
evergrow
field
viral
vector
research
vector
well
character
basic
virolog
vector
complex
immun
respons
elicit
vaccin
other
still
incomplet
understood
studi
use
viral
vector
advanc
field
human
gene
therapi
genet
diseas
cancer
gene
therapi
vaccin
develop
continu
expand
scientif
horizon
